Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Dexmethylphenidate methyl (2S)-2-phenyl-2-[(2R)-2...

Synonyms: D-MPH, CHEMBL827, SureCN34326, CHEBI:51860, DNC014476, ...

Keating, G.M. et al., Aoyama, T. et al., Quinn, D. et al., Kimko, H.C. et al., McGough, J.J. et al., et al.

Silva, Tilker, Cecil, Kowalik, Khetani, Faleck, Patin, McGough, Pataki, Suddath, Kimko, Cross, Abernethy, Greenhill, Muniz, Ball, Levine, Pestreich, Jiang,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Psychiatry related information on d-threo-Methylphenidate

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder [1].
Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers [2].

High impact information on d-threo-Methylphenidate

Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder [3].
In the same study, parent-rated SNAP-ADHD scores had decreased by a significantly greater extent in dexmethylphenidate recipients at 3pm and 6pm and in methylphenidate recipients at 3pm, compared with placebo recipients [4].
Dose-Proportional Pharmacokinetics of d-threo-Methylphenidate After a Repeated-Action Release Dosage Form [5].
A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects [6].
Optical purity determination of threo-methylphenidate hydrochloride using a chiral europium nuclear magnetic resonance (NMR) shift reagent [7].

Chemical compound and disease context of d-threo-Methylphenidate

Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder [8].

Associations of d-threo-Methylphenidate with other chemical compounds

If variable stereoselective metabolism occurs clinically, therapeutic drug monitoring of methylphenidate will require the application of chiral assay methods for the analysis of the active component, d-threo-methylphenidate [9].
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder [10].
Dexmethylphenidate extended release is a long-acting preparation of the ADHD medication Focalin (dexmethylphenidate immediate release) and was approved for marketing by the US Food and Drug administration in June 2005 [11].

Gene context of d-threo-Methylphenidate

Significantly fewer dexmethylphenidate than placebo recipients failed treatment in a double-blind, treatment-withdrawal trial in 75 children with ADHD (17.1 vs 61.5%) [4].
In a noncomparative study in 22 children with ADHD, symptoms of ADHD, as assessed by teachers and parents, were controlled during the entire school day in 68 and 86% of dexmethylphenidate recipients, respectively, with a median duration of effect of 6.3 and 7.5 hours, respectively [4].

Analytical, diagnostic and therapeutic context of d-threo-Methylphenidate

Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method [12].

References

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. Greenhill, L.L., Muniz, R., Ball, R.R., Levine, A., Pestreich, L., Jiang, H. Journal of the American Academy of Child and Adolescent Psychiatry. (2006) [Pubmed]
Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Aoyama, T., Kotaki, H., Sasaki, T., Sawada, Y., Honda, Y., Iga, T. Eur. J. Clin. Pharmacol. (1993) [Pubmed]
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder. Robinson, D.M., Keating, G.M. Drugs (2006) [Pubmed]
Dexmethylphenidate. Keating, G.M., Figgitt, D.P. Drugs (2002) [Pubmed]
Dose-Proportional Pharmacokinetics of d-threo-Methylphenidate After a Repeated-Action Release Dosage Form. Tuerck, D., Appel-Dingemanse, S., Maboudian, M., Pommier, F., Wang, Y., Sedek, G. Journal of clinical pharmacology (2007) [Pubmed]
A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. Teo, S.K., Scheffler, M.R., Wu, A., Stirling, D.I., Thomas, S.D., Stypinski, D., Khetani, V.D. Journal of clinical pharmacology. (2004) [Pubmed]
Optical purity determination of threo-methylphenidate hydrochloride using a chiral europium nuclear magnetic resonance (NMR) shift reagent. Hanna, G.M., Lau-Cam, C.A. Pharm. Res. (1990) [Pubmed]
Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. Quinn, D., Wigal, S., Swanson, J., Hirsch, S., Ottolini, Y., Dariani, M., Roffman, M., Zeldis, J., Cooper, T. Journal of the American Academy of Child and Adolescent Psychiatry. (2004) [Pubmed]
Pharmacokinetics and clinical effectiveness of methylphenidate. Kimko, H.C., Cross, J.T., Abernethy, D.R. Clinical pharmacokinetics. (1999) [Pubmed]
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. Silva, R., Tilker, H.A., Cecil, J.T., Kowalik, S., Khetani, V., Faleck, H., Patin, J. Journal of child and adolescent psychopharmacology. (2004) [Pubmed]
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. McGough, J.J., Pataki, C.S., Suddath, R. Expert review of neurotherapeutics. (2005) [Pubmed]
Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. Aoyama, T., Kotaki, H., Honda, Y., Nakagawa, F. Journal of pharmaceutical sciences. (1990) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.